WHO conducts first trial of Ebola antiviral developed by US firm

WHO launches first clinical trial of antiviral obeldesivir for Ebola post-exposure prophylaxis.

The trial, named EBO-PEP, targets the Bundibugyo Ebola strain spreading in the Democratic Republic of Congo.

Obeldesivir was developed by a US firm and aims to prevent infection in people exposed to confirmed cases.